101 
Market Cap
As of July 16, 2010: $79,905,000.00
Stock Chart
Alchemia - 30 Day Poll
Recent BLOGS About Alchemia Add New
There are no blogs to display.
Latest Company News
|
Alchemia and Dr Reddy’s Expand Fondaparinux Marketing Collaboration
Business Wire - Jul 15, 2010 BRISBANE, Australia--(BUSINESS WIRE)--Alchemia (ASX:ACL) today announced the agreement of terms with Dr Reddy's Limited for marketing fondaparinux sodium for injection (the generic version of ...
Alchemia and Dr Reddy’s Expand Fondaparinux Marketing Collaboration - EarthtimesAlchemia signs expanded marketing agreement with Dr Reddy's for fondaparinux - Trading Markets |
|
Alchemia Limited And Dr Reddy’s Expand Fondaparinux Marketing Collaboration
Reuters Key Development - Jul 14, 2010 |
|
Alchemia’s HyACT Technology Enhances the Killing of Cancer Stem Cell Populations in Breast and Colorectal Cancer
Business Wire - Apr 21, 2010 BRISBANE, Australia--(BUSINESS WIRE)--Alchemia's (ASX: ACL) subsidiary Alchemia Oncology today presented two posters at the American Association of Cancer Research (AACR) 101 st Annual Meeting in ...
Alchemia's HyACT tumour targeting technology enhances killing of cancer stem cells - News-Medical.net |
|
Emisphere Technologies, Inc. And Alchemia Ltd. To Research An Oral Formulation Of Fondaparinux With Eligen Technology
Reuters Key Development - Mar 18, 2010 |
|
Alchemia Limited Announces Completion Of Allotment And Issue Of Rights Issue Shares
Reuters Key Development - Jan 5, 2010 |
Website
Videos related to Alchemia
Company Profile
Consolidated cash position was $19.7 million in March 2010
Upcoming Events:
- Product launch of syntheic heaprin (calendar year 2010)
- Phase II colorectal cancer trial (September 2010)
Alchemia is a biotechnology company with particular expertise in chemistry.
Highlights:
- Near revenues for synthetic Heparin
- Positive results for colorectal cancer Phase II trial
- the HyACTdrug delivery platform Alchemia's antithrombotic drug, generic heparin, is the Company's primary opportunity and targets the multi-billion dollar heparin-drug market and is expected to be generating revenues in 2010.
Fondaparinux is may have a superior safety and efficacy relative to the market leading drug Lovenoxand. Alchemia's product is very difficult to synthesize and therefore it is possible that there will be limited competition from other generics.
HA-irinotecan is Alchemia's most advanced anticancer product. It combines the chemotherapeutic drug irinotecan (Pfizer's Camptosar) with hyaluronic acid (HA). In May 2007, Alchemia reported positive results from a Phase II clinical trial. HA-irinotecan not only allowed more cycles of irinotecan to be administered to cancer patients, but also produced significant disease control and a doubling in progression free survival.
The HyACTdrug delivery platform presents multiple product opportunities. HyACTimproves the delivery of chemotherapeutic agents to cancer cells. HyACTboosts drug efficacy and reduces unwanted side effects. The technology also has applications and is applicable to other therapeutic agents from small molecule cytotoxics to much larger biologics (i.e. monoclonal antibodies). For HA-irinotecan, the lead product, Alchemia has successfully completed a Phase II clinical trail in colorectal cancer patients.
Phase III patient enrolment for the colorectal cancer drug candidiate may begin in September 2010.
Possible Competitors
Apicore LLC has filed for a possible equivalent generic heparin with the FDA
Upcoming Events:
- Product launch of syntheic heaprin (calendar year 2010)
- Phase II colorectal cancer trial (September 2010)
Alchemia is a biotechnology company with particular expertise in chemistry.
Highlights:
- Near revenues for synthetic Heparin
- Positive results for colorectal cancer Phase II trial
- the HyACTdrug delivery platform Alchemia's antithrombotic drug, generic heparin, is the Company's primary opportunity and targets the multi-billion dollar heparin-drug market and is expected to be generating revenues in 2010.
Fondaparinux is may have a superior safety and efficacy relative to the market leading drug Lovenoxand. Alchemia's product is very difficult to synthesize and therefore it is possible that there will be limited competition from other generics.
HA-irinotecan is Alchemia's most advanced anticancer product. It combines the chemotherapeutic drug irinotecan (Pfizer's Camptosar) with hyaluronic acid (HA). In May 2007, Alchemia reported positive results from a Phase II clinical trial. HA-irinotecan not only allowed more cycles of irinotecan to be administered to cancer patients, but also produced significant disease control and a doubling in progression free survival.
The HyACTdrug delivery platform presents multiple product opportunities. HyACTimproves the delivery of chemotherapeutic agents to cancer cells. HyACTboosts drug efficacy and reduces unwanted side effects. The technology also has applications and is applicable to other therapeutic agents from small molecule cytotoxics to much larger biologics (i.e. monoclonal antibodies). For HA-irinotecan, the lead product, Alchemia has successfully completed a Phase II clinical trail in colorectal cancer patients.
Phase III patient enrolment for the colorectal cancer drug candidiate may begin in September 2010.
Possible Competitors
Apicore LLC has filed for a possible equivalent generic heparin with the FDA
Terms & Rules
As per ASIC Regulatory Guide 162: All investment tips and comments appearing on this website (Poll results, BLOGS & discussion forums) are submitted by the general public who are not licensed financial advisors. None of the information on this website is financial or investment advice, you should seek independent financial or investment advice by a licensed financial or investment advisor before entering into any position of financial risk. Before using this website, you must agree to the BioInvesting.com.au Terms Of Use